FAK regulation of cholesterol influx and efflux in foam cells
FAK regulation of cholesterol influx and efflux in foam cells
批准号:
10729865
负责人:
Steve Lim
金额:
$36.48万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-08-01 至 2025-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Atherosclerosis arises as a result of excess accumulation of cholesterol within vascular cells, with
macrophages comprising a majority of these lipid-laden foam cells within atherosclerotic lesions. Lipid-lowering
therapies, such as statins, have proven beneficial, but still only benefit a subset of patients. As such, there is
currently a need to develop new treatment options that can treat a larger portion of atherosclerosis patients to
reduce cardiovascular disease mortality. One potential strategy for treating atherosclerosis is to reduce foam
cells by decreasing cholesterol uptake (influx) and/or to promote cholesterol release (efflux) in macrophages.
However, no current therapy targets these mechanisms. Foam cells within atherosclerotic lesions are
developed from too much cholesterol influx without efficient efflux. Focal adhesion kinase (FAK) is an integrin-
associated tyrosine kinase which contributes to vascular cell migration, proliferation, and inflammation. We
have discovered new functions for FAK in the regulation of lipid homeostasis within macrophages. Our
preliminary data revealed that FAK activation following oxidized low-density lipoprotein (oxLDL) stimulation
was required for foam cell formation via endocytosis of CD36. Additionally, oxLDL increased FAK interaction
with CD36 and Filamin A. Importantly, pharmacological FAK inhibition blocked FAK-CD36-Filamin A interaction
and subsequent foam cell formation, suggesting that the ternary complex may contribute to oxLDL uptake.
More interestingly, FAK inhibition increased expression of cellular lipid sensors peroxisome proliferator
activated receptor g (PPARg) and liver X receptor a (LXRa) resulting in increased transcription of the
cholesterol antiporters ABCG1 and ABCA1. FAK inhibition also increased PPARg and LXRa nuclear
translocation, and this was associated with decreased expression of nuclear receptor corepressor 2 (NCOR2).
In a new macrophage-specific FAK kinase-dead (KD) mouse model (CSF1R-iCre) on ApoE-/- background, we
observed that FAK-KD mice fed a western diet (WD) showed less foam cell formation and reduced
atherosclerotic lesions. Taken together, our central hypothesis is that FAK inhibition reduces oxLDL uptake via
disruption of FAK-Filamin A-CD36 complex formation while also increasing cholesterol efflux through increased
PPARg and LXRa activation via NCOR2 degradation. To decipher a molecular mechanism in which a two-fold
role of FAK prevents cholesterol uptake as well as enhances efflux in macrophages. Aim 1 will determine FAK
and Filamin A regulation of oxLDL-CD36 uptake in macrophages. Aim 2 will investigate FAK regulation of
cholesterol efflux via PPARg and LXRa activation in foam cells. Aim 3 will evaluate the effect of FAK inhibition
on preventive and therapeutic models of atherosclerosis. The proposed study will shed new insights on the role
of FAK in cholesterol homeostasis in macrophage foam cells and could produce a new treatment option in
atherosclerosis by reducing the foam cells via reduced cholesterol influx and elevated cholesterol efflux.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nuclear FAK-mediated VSMC differentiation via epigenetic reprograming invascular diseases
-
批准号:10584581
-
项目类别:
-
资助金额:$47.54万
-
财政年份:2022
-
负责人:Steve Lim
-
依托单位:
Nuclear FAK-mediated VSMC differentiation via epigenetic reprograming invascular diseases
-
批准号:10618482
-
项目类别:
-
资助金额:$47.54万
-
财政年份:2022
-
负责人:Steve Lim
-
依托单位:
FAK regulation of cholesterol influx and efflux in foam cells
-
批准号:10640873
-
项目类别:
-
资助金额:$36.97万
-
财政年份:2021
-
负责人:Steve Lim
-
依托单位:
FAK regulation of cholesterol influx and efflux in foam cells
-
批准号:10278516
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2021
-
负责人:Steve Lim
-
依托单位:
FAK regulation of cholesterol influx and efflux in foam cells
-
批准号:10427440
-
项目类别:
-
资助金额:$0.67万
-
财政年份:2021
-
负责人:Steve Lim
-
依托单位:
Role of FAK in vascular inflammation
-
批准号:9886279
-
项目类别:
-
资助金额:$42.65万
-
财政年份:2017
-
负责人:Steve Lim
-
依托单位:
国内基金
海外基金
登录
查看更多内容
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
-
批准号:82371634
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵福军
-
依托单位:
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
-
批准号:82371651
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵栋
-
依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
-
批准号:82370798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王晓
-
依托单位:
精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
-
批准号:82371770
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:宁铂涛
-
依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
-
批准号:82371801
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:周海波
-
依托单位:
TIPE2调控巨噬细胞M2极化改善睑板腺功能障碍的作用机制研究
-
批准号:82371028
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵慧
-
依托单位:
亚低温调控颅脑创伤急性期神经干细胞Mpc2/Lactate/H3K9lac通路促进神经修复的研究
-
批准号:82371379
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:冯军峰
-
依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
-
批准号:82372275
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘耀宝
-
依托单位:
α-酮戊二酸调控ACMSD介导犬尿氨酸通路代谢重编程在年龄相关性听力损失中的作用及机制研究
-
批准号:82371150
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:侯书乐
-
依托单位:
mPFC-VTA-NAc多巴胺能投射调控丙泊酚麻醉—觉醒的机制研究
-
批准号:82371284
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:许涛
-
依托单位: